Bonen D K, Hausman A M, Hadjiagapiou C, Skarosi S F, Davidson N O
Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA.
J Biol Chem. 1997 Feb 28;272(9):5659-67. doi: 10.1074/jbc.272.9.5659.
Apolipoprotein(a) (apo(a)), a large glycoprotein with extensive homology to plasminogen, forms a complex with apolipoprotein B100 (apoB100), which circulates in human plasma in the form of lipoprotein(a) (Lp(a)). Evidence indicates that the association of apo(a) with apoB100 occurs in the extracellular environment. We have reevaluated the possibility that apo(a)-B100 association can also occur as an intracellular event through studies with HepG2 cells stably transfected with an apo(a) minigene. Several lines of evidence support this possibility. First, continued Lp(a) production was demonstrated following incubation of transfected HepG2 cells with anti-apo(a) antisera, conditions that effectively block the fluid-phase association of apo(a) and apoB100 in vitro. Second, an apo(a)-B100 complex was detectable in Western blot analyses of transfected HepG2 lysates following immunoprecipitation with anti-apo(a) antisera. These studies incorporated precautions to eliminate cell-surface attachment of preformed apo(a)-B100 complexes to the low density lipoprotein receptor and were conducted in the presence of the lysine analog epsilon-aminocaproic acid, which precludes apo(a)-B100 association occurring during the isolation and analyses. Third, the presence of an intracellular apo(a)-B100 complex was demonstrated in lipoproteins isolated from microsomal contents. Of particular significance was the observation that this complex contained the precursor form of apo(a), which is not secreted, in addition to the mature, recombinant form. Finally, direct evidence was provided for the synthesis of a precursor form of apo(a) in a nascent intracellular complex with apoB100 following treatment of transfected HepG2 cells with brefeldin A plus N-acetyl-leucyl-leucyl-norleucinal. Taken together, these data suggest that apo(a)-B100 association can occur as an intracellular event in a human hepatoma-derived cell line, raising important implications for the regulation of Lp(a) secretion from human liver.
载脂蛋白(a)[apo(a)]是一种与纤溶酶原具有广泛同源性的大型糖蛋白,它与载脂蛋白B100(apoB100)形成复合物,以脂蛋白(a)[Lp(a)]的形式在人体血浆中循环。有证据表明,apo(a)与apoB100的结合发生在细胞外环境中。我们通过对稳定转染apo(a)小基因的HepG2细胞进行研究,重新评估了apo(a)-B100结合也可能作为细胞内事件发生的可能性。几条证据支持了这种可能性。首先,用抗apo(a)抗血清孵育转染的HepG2细胞后,持续产生Lp(a),这些条件在体外有效地阻断了apo(a)和apoB100的液相结合。其次,在用抗apo(a)抗血清进行免疫沉淀后,在转染的HepG2裂解物的蛋白质印迹分析中可检测到apo(a)-B100复合物。这些研究采取了预防措施,以消除预先形成的apo(a)-B100复合物与低密度脂蛋白受体的细胞表面附着,并在赖氨酸类似物ε-氨基己酸存在的情况下进行,该物质可防止在分离和分析过程中发生apo(a)-B100结合。第三,在从微粒体内容物中分离的脂蛋白中证实了细胞内apo(a)-B100复合物的存在。特别重要的是观察到该复合物除了含有成熟的重组形式外,还含有未分泌的apo(a)前体形式。最后,在用布雷菲德菌素A加N-乙酰-亮氨酰-亮氨酰-正亮氨酸处理转染的HepG2细胞后,为在与apoB100的新生细胞内复合物中合成apo(a)前体形式提供了直接证据。综上所述,这些数据表明apo(a)-B100结合可以作为一种细胞内事件发生在人肝癌衍生细胞系中,这对人肝脏中Lp(a)分泌的调节具有重要意义。